Immune Pharmaceuticals Company Profile (NASDAQ:IMNP)

About Immune Pharmaceuticals

Immune Pharmaceuticals logoImmune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IMNP
  • CUSIP:
Key Metrics:
  • Previous Close: $0.28
  • 50 Day Moving Average: $0.354
  • 200 Day Moving Average: $0.392
  • 52-Week Range: $0.20 - $1.54
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 9.23
  • P/E Growth: 0.000
  • Market Cap: $21.93M
  • Outstanding Shares: 79,178,000
  • Beta: 1.47
Profitability:
  • Return on Equity: -274.69%
  • Return on Assets: -58.60%
Debt:
  • Debt-to-Equity Ratio: 0.45%
  • Current Ratio: 0.10%
  • Quick Ratio: 0.10%
Additional Links:
Companies Related to Immune Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Immune Pharmaceuticals (NASDAQ:IMNP) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.25 (2,156.32% upside)

Analysts' Ratings History for Immune Pharmaceuticals (NASDAQ:IMNP)
Show:
DateFirmActionRatingPrice TargetDetails
9/18/2016FBR & CoReiterated RatingBuyView Rating Details
5/16/2016Chardan CapitalReiterated RatingBuyView Rating Details
4/4/2016Roth CapitalReiterated RatingBuyView Rating Details
6/11/2015MLV & Co.Initiated CoverageBuy$6.00View Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Immune Pharmaceuticals (NASDAQ:IMNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
8/16/2016Q2($0.13)($0.13)ViewN/AView Earnings Details
5/16/2016Q116($0.15)($0.17)ViewN/AView Earnings Details
11/12/2015Q315($0.18)($0.35)ViewListenView Earnings Details
8/17/2015Q215($0.22)($0.12)ViewN/AView Earnings Details
5/18/2015Q1($0.20)($0.15)ViewN/AView Earnings Details
4/15/2015($0.37)($0.34)ViewN/AView Earnings Details
8/14/2014($0.21)($0.27)ViewN/AView Earnings Details
5/22/2014($0.15)($0.35)ViewN/AView Earnings Details
4/11/2014($0.15)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Immune Pharmaceuticals (NASDAQ:IMNP)
Current Year EPS Consensus Estimate: $-0.560 EPS
Next Year EPS Consensus Estimate: $0.030 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.15)($0.15)($0.15)
Q2 20161($0.14)($0.14)($0.14)
Q3 20162($0.14)($0.13)($0.14)
Q4 20162($0.15)($0.11)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immune Pharmaceuticals (NASDAQ:IMNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Immune Pharmaceuticals (NASDAQ:IMNP)
Insider Ownership Percentage: 17.83%
Institutional Ownership Percentage: 0.56%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/4/2016Daniel Gedeon TeperCEOBuy937,500$0.38$356,250.00View SEC Filing  
8/4/2016Daniel KazadoDirectorBuy666,667$0.45$300,000.15View SEC Filing  
8/4/2016Monica E LuchiCMOBuy777,778$0.45$350,000.10View SEC Filing  
1/26/2016Daniel Gedeon TeperCEOBuy42,000$0.59$24,780.00View SEC Filing  
1/19/2016Daniel Gedeon TeperCEOBuy44,200$0.57$25,194.00View SEC Filing  
1/12/2016Daniel Gedeon TeperCEOBuy39,400$0.62$24,428.00View SEC Filing  
1/5/2016Daniel Gedeon TeperCEOBuy62,000$0.81$50,220.00View SEC Filing  
12/7/2015Daniel Gedeon TeperCEOBuy65,400$0.76$49,704.00View SEC Filing  
12/7/2015Daniel KazadoDirectorBuy150,000$0.78$117,000.00View SEC Filing  
10/26/2015Daniel Gedeon TeperCEOBuy18,400$1.36$25,024.00View SEC Filing  
10/19/2015Daniel Gedeon TeperCEOBuy18,600$1.34$24,924.00View SEC Filing  
10/12/2015Daniel Gedeon TeperCEOBuy19,000$1.30$24,700.00View SEC Filing  
10/5/2015Daniel Gedeon TeperCEOBuy40,700$1.23$50,061.00View SEC Filing  
9/14/2015Rene Pierre AzriaDirectorBuy50,000$1.48$74,000.00View SEC Filing  
9/1/2015Daniel Gedeon TeperCEOBuy7,569$1.29$9,764.01View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Immune Pharmaceuticals (NASDAQ:IMNP)
DateHeadline
News IconActive Movers: Immune Pharmaceuticals Inc (NASDAQ:IMNP), Macy's Inc (NYSE:M) - NYSE Journal (press release) (NASDAQ:IMNP)
stockznews.com - September 27 at 10:13 AM
News IconHot Biotech Stocks To Watch Right Now: Celgene Corporation (CELG), Immune Pharmaceuticals, Inc. (IMNP) - The Independent Republic (NASDAQ:IMNP)
theindependentrepublic.com - September 26 at 5:43 PM
News IconTrader's Radar- Immune Pharmaceuticals Inc. (NASDAQ:IMNP) - Hot Stocks Point (NASDAQ:IMNP)
www.hotstockspoint.com - September 24 at 10:06 AM
News IconHC Stocks Watchful! Immune Pharmaceuticals Inc (IMNP), Envision ... - share market updates (press release) (NASDAQ:IMNP)
sharemarketupdates.com - September 23 at 5:17 PM
News IconKeen Investors Find News on Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - Duncan Research (NASDAQ:IMNP)
www.duncanindependent.com - September 23 at 5:17 PM
News IconUnder the Microscope, Zeroing in at Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - Duncan Research (NASDAQ:IMNP)
www.duncanindependent.com - September 22 at 3:39 PM
News IconImmune Pharmaceuticals Inc. (NASDAQ:IMNP) Analytical Report - Newburgh Press (NASDAQ:IMNP)
newburghpress.com - September 22 at 3:39 PM
News IconStocks Tumbling on Lethargic Results: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP), Quest Diagnostics Inc. (NYSE ... - Street Wise Report (press release) (blog) (NASDAQ:IMNP)
streetwisereport.com - September 19 at 5:40 PM
streetinsider.com logoImmune Pharma (IMNP) Board Approves Dedicated Subsidiary to Develop AmiKet; Enters Funding Arrangement (NASDAQ:IMNP)
www.streetinsider.com - September 17 at 10:11 AM
News IconStocks Under Street Preference- Aerie Pharmaceuticals (NASDAQ:AERI), Immune Pharmaceuticals (IMNP) - Seneca Globe (NASDAQ:IMNP)
www.senecaglobe.com - September 16 at 5:28 PM
streetinsider.com logoImmune Pharma (IMNP) Board Approves Dedicated Subsidiary to Develop AmiKet; Enters Funding Arrangement - StreetInsider.com (NASDAQ:IMNP)
www.streetinsider.com - September 16 at 9:31 AM
biz.yahoo.com logoIMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St (NASDAQ:IMNP)
biz.yahoo.com - September 16 at 9:31 AM
News IconHC Stocks Analysis= Clovis Oncology Inc (CLVS), Immune Pharmaceuticals Inc (NASDAQ:IMNP) - share market updates (press release) (NASDAQ:IMNP)
sharemarketupdates.com - September 15 at 8:48 AM
News IconHC Stocks Watchful= Zoetis Inc (ZTS), Immune Pharmaceuticals Inc (NASDAQ:IMNP) - share market updates (press release) (NASDAQ:IMNP)
sharemarketupdates.com - September 12 at 5:30 PM
News IconInphi Tumbles 3.7% on Planned $200 Mln Notes Offering (NYSE:IPHI) (NASDAQ:IMNP)
magseriesusa.net - September 7 at 5:46 PM
finance.yahoo.com logoImmune Pharmaceuticals Receives $2 Million Investment in Common Stock at $0.50 per Share (NASDAQ:IMNP)
finance.yahoo.com - September 7 at 9:01 AM
biz.yahoo.com logoIMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E (NASDAQ:IMNP)
biz.yahoo.com - September 7 at 9:01 AM
finance.yahoo.com logo7:35 am Immune Pharma enters into stock purchase agreement with an existing stockholder for the sale of 4 mln shares of common stock at a fixed price of $0.50/share (NASDAQ:IMNP)
finance.yahoo.com - September 7 at 9:01 AM
News IconTraders Alert: Immune Pharmaceuticals Inc (NASDAQ:IMNP), Mitsubishi UFJ Financial Group Inc (ADR)(NYSE:MTU ... - NYSE Journal (press release) (NASDAQ:IMNP)
stockznews.com - September 2 at 5:34 PM
wallstrt24.com logoStock's Buzzers - CONSOL Energy, (NYSE:CNX), Immune Pharmaceuticals, (NASDAQ:IMNP), Gilead Sciences ... - Wall Street 24 (NASDAQ:IMNP)
wallstrt24.com - August 31 at 10:26 AM
News IconShares in the Trader's Spot light- Immune Pharmaceuticals, Inc.'s (IMNP) - Hot Stocks Point (NASDAQ:IMNP)
www.hotstockspoint.com - August 31 at 10:26 AM
finance.yahoo.com logoIMMUNE PHARMACEUTICALS INC Financials (NASDAQ:IMNP)
finance.yahoo.com - August 24 at 5:30 PM
News IconFirst Pacific Advisors buys $281669172 stake in Thermo Fisher Scientific (TMO) (NASDAQ:IMNP)
myhealthbowl.com - August 20 at 9:48 AM
biz.yahoo.com logoIMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:IMNP)
biz.yahoo.com - August 18 at 5:38 PM
News IconNoble Corporation Ordinary Shares (NYSE:NE) & Immune Pharmaceuticals (NASDAQ:IMNP) Investor's Alert - Money News (press release) (NASDAQ:IMNP)
www.newsismoney.com - August 17 at 5:50 PM
News IconStock Earnings in Review: Immune Pharmaceuticals Inc (NASDAQ:IMNP) - Post Registrar (NASDAQ:IMNP)
postregistrar.com - August 17 at 5:50 PM
News IconHvad skete der lige der? (NASDAQ:IMNP)
www.euroinvestor.dk - August 16 at 5:48 PM
finance.yahoo.com logoImmune Pharmaceuticals Provides Business and R&D Update and Announces Second Quarter 2016 Financial Results (NASDAQ:IMNP)
finance.yahoo.com - August 16 at 11:51 AM
biz.yahoo.com logoIMMUNE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:IMNP)
biz.yahoo.com - August 15 at 8:47 PM
News IconAnalysts Review on Earnings Estimates: Immune Pharmaceuticals Inc (NASDAQ:IMNP) - Post Registrar (NASDAQ:IMNP)
postregistrar.com - August 15 at 3:16 PM
4-traders.com logoLife Clips : Earnings Season is Here and These 4 Companies Deserve Your Attention (NASDAQ:IMNP)
www.4-traders.com - August 11 at 5:53 PM
News IconFriendable, Inc. (OTC Pink: FDBL) – Re-Signs TKA – More Celebrity Endorsements, Adds Consumer Brand Partnerships (NASDAQ:IMNP)
ih.advfn.com - August 11 at 5:53 PM
News IconHigh Volume Healthcare Stocks Movements: Merck & Co., Inc. (NYSE:MRK), Immune Pharmaceuticals, Inc. (NASDAQ ... - TWN (NASDAQ:IMNP)
thewellesleysnews.com - August 10 at 8:32 AM
streetupdates.com logoAnalysts Review of Stocks: Immune Pharmaceuticals Inc. (NASDAQ:IMNP) , Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Street Updates (NASDAQ:IMNP)
www.streetupdates.com - August 9 at 5:48 PM
News IconHigh Volume Healthcare Stocks: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP), MEI Pharma, Inc. (NASDAQ:MEIP) - TWN (NASDAQ:IMNP)
thewellesleysnews.com - August 9 at 5:48 PM
seekingalpha.com logoImmune Pharmaceuticals: The Million Dollar Mistake - Seeking Alpha (NASDAQ:IMNP)
seekingalpha.com - August 9 at 5:48 PM
News IconHC Stocks to Path: Immune Pharmaceuticals Inc (NASDAQ:IMNP) Celgene Corporation (NASDAQ:CELG) - share market updates (press release) (NASDAQ:IMNP)
sharemarketupdates.com - August 9 at 8:38 AM
News IconOppe med 7% i pm (NASDAQ:IMNP)
www.euroinvestor.dk - August 8 at 5:50 PM
News IconCEO of Immune Pharmaceuticals Inc (NASDAQ:IMNP), Teper Daniel Gedeon, buys 937,500 shares worth $356,250 (NASDAQ:IMNP)
empowerednews.net - August 5 at 5:45 PM
istreetwire.com logo3 Stocks in Focus: Under Armour, Inc. (UA), Immune Pharmaceuticals, Inc. (IMNP), Cray Inc. (CRAY) - iStreetWire (NASDAQ:IMNP)
istreetwire.com - August 5 at 8:35 AM
streetupdates.com logoStocks within Traders Radar: Endo International plc (NASDAQ:ENDP) , Immune Pharmaceuticals Inc. (NASDAQ:IMNP) - Street Updates (NASDAQ:IMNP)
www.streetupdates.com - August 5 at 8:35 AM
fortune.com logoAnalyst Views That Are Worth Watching: Immune Pharmaceuticals Inc (NASDAQ:IMNP), Cray Inc. (NASDAQ:CRAY) - Review Fortune (NASDAQ:IMNP)
reviewfortune.com - August 5 at 8:35 AM
gurufocus.com logoImmune Pharmaceuticals Inc (IMNP) CEO Daniel Gedeon Teper Bought $356250 of Stocks - GuruFocus.com (NASDAQ:IMNP)
www.gurufocus.com - August 5 at 8:35 AM
finance.yahoo.com logoImmune Pharmaceuticals Inc (IMNP) CEO Daniel Gedeon Teper Bought $356,250 of Stocks (NASDAQ:IMNP)
finance.yahoo.com - August 5 at 8:35 AM
istreetwire.com logoTraders Recap: Evoke Pharma, Inc. (EVOK), Immune Pharmaceuticals, Inc. (IMNP), InvenSense, Inc. (INVN) - iStreetWire (NASDAQ:IMNP)
istreetwire.com - August 4 at 8:38 AM
istreetwire.com logoTraders Recap: Evoke Pharma, Inc. (EVOK), Immune Pharmaceuticals, Inc. (IMNP), InvenSense, Inc. (INVN) (NASDAQ:IMNP)
istreetwire.com - August 3 at 5:56 PM
biz.yahoo.com logoIMMUNE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit (NASDAQ:IMNP)
biz.yahoo.com - August 3 at 5:56 PM
streetupdates.com logoNoteworthy Analyst's Rating to Observe: Boston Scientific Corporation (NYSE:BSX) , Immune Pharmaceuticals Inc ... - Street Updates (NASDAQ:IMNP)
www.streetupdates.com - July 27 at 8:26 AM
News IconStock under consideration: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) - News Oracle (NASDAQ:IMNP)
www.newsoracle.com - July 27 at 8:26 AM
istreetwire.com logoStocks Trending Alert: Ross Stores Inc. (ROST), Immune Pharmaceuticals, Inc. (IMNP), Raytheon Company (RTN) - iStreetWire (NASDAQ:IMNP)
istreetwire.com - July 26 at 8:34 AM

Social

Immune Pharmaceuticals (NASDAQ:IMNP) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff